The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Combination delivery of TGF-β inhibitor and IL-2 by nanoscale liposomal polymeric gels enhances tumour immunotherapy
Open accessAbstract
The tumour microenvironment thwarts conventional immunotherapy through multiple immunologic mechanisms, such as the secretion of the transforming growth factor-β (TGF-β), which stunts local tumour immune responses. Therefore, high doses of interleukin-2 (IL-2), a conventional cytokine for metastatic melanoma, induces only limited responses. To overcome the immunoinhibitory nature of the tumour microenvironment, we developed nanoscale liposomal polymeric gels (nanolipogels; nLGs) of drug-complexed cyclodextrins and cytokine-encapsulating biodegradable polymers that can deliver small hydrophobic molecular inhibitors and water-soluble protein cytokines in a sustained fashion to the tumour microenvironment. nLGs releasing TGF-β inhibitor and IL-2 significantly delayed tumour growth, increased survival of tumour-bearing mice, and increased the activity of natural killer cells and of intratumoral-activated CD8+ T-cell infiltration. We demonstrate that the efficacy of nLGs in tumour immunotherapy results from a crucial mechanism involving activation of both innate and adaptive immune responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Long-Circulating and Target-Specific Nanoparticles: Theory to Practice
Moghimi, S. M., Hunter, A. C., & Murray, J. C. (2001) · Pharmacological Reviews · doi:10.1016/s0031-6997(24)01494-7 · Cited by 3,515
Atkins, M. B., Lotze, M. T., Dutcher, J. P., Fisher, R. I., Weiss, G., Margolin, K., Abrams, J., Sznol, M., Parkinson, D., Hawkins, M., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.7.2105 · Cited by 2,048
Multifunctional Inorganic Nanoparticles for Imaging, Targeting, and Drug Delivery
Liong, M., Lu, J., Kovochich, M., Xia, T., Ruehm, S. G., Nel, A. E., Tamanoi, F., & Zink, J. I. (2008) · ACS Nano · doi:10.1021/nn800072t · Cited by 1,929
SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS
Feng, X.-H., & Derynck, R. (2005) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.21.022404.142018 · Cited by 1,869
Cyclodextrins and their pharmaceutical applications
LOFTSSON, T., & DUCHENE, D. (2007) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2006.10.044 · Cited by 1,764
Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo
Farokhzad, O. C., Cheng, J., Teply, B. A., Sherifi, I., Jon, S., Kantoff, P. W., Richie, J. P., & Langer, R. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0601755103 · Cited by 1,663
Moghimi, S. M., & Szebeni, J. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(03)00033-x · Cited by 1,227
Mundargi, R. C., Babu, V. R., Rangaswamy, V., Patel, P., & Aminabhavi, T. M. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.09.013 · Cited by 1,025
Ashley, C. E., Carnes, E. C., Phillips, G. K., Padilla, D., Durfee, P. N., Brown, P. A., Hanna, T. N., Liu, J., Phillips, B., Carter, M. B., et al. (2011) · Nature Materials · doi:10.1038/nmat2992 · Cited by 1,024
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020
Sawhney, A. S., Pathak, C. P., & Hubbell, J. A. (1993) · Macromolecules · doi:10.1021/ma00056a005 · Cited by 974
The polarization of immune cells in the tumour environment by TGFβ
Flavell, R. A., Sanjabi, S., Wrzesinski, S. H., & Licona-Limón, P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2808 · Cited by 940
Self-citationMeng, H., Liong, M., Xia, T., Li, Z., Ji, Z., Zink, J. I., & Nel, A. E. (2010) · ACS Nano · doi:10.1021/nn100690m · Cited by 902
Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles
Wischke, C., & Schwendeman, S. P. (2008) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2008.04.042 · Cited by 790
Gorelik, L., & Flavell, R. A. (2001) · Nature Medicine · doi:10.1038/nm1001-1118 · Cited by 770
Self-citationStella, V. J., & He, Q. (2008) · Toxicologic Pathology · doi:10.1177/0192623307310945 · Cited by 700
Meng, H., Xue, M., Xia, T., Zhao, Y.-L., Tamanoi, F., Stoddart, J. F., Zink, J. I., & Nel, A. E. (2010) · Journal of the American Chemical Society · doi:10.1021/ja104501a · Cited by 595
Moon, J. J., Suh, H., Bershteyn, A., Stephan, M. T., Liu, H., Huang, B., Sohail, M., Luo, S., Ho Um, S., Khant, H., et al. (2011) · Nature Materials · doi:10.1038/nmat2960 · Cited by 564
Development of TGF-β signalling inhibitors for cancer therapy
Yingling, J. M., Blanchard, K. L., & Sawyer, J. S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1580 · Cited by 549
Systemic Leukocyte-Directed siRNA Delivery Revealing Cyclin D1 as an Anti-Inflammatory Target
Peer, D., Park, E. J., Morishita, Y., Carman, C. V., & Shimaoka, M. (2008) · Science · doi:10.1126/science.1149859 · Cited by 493
Liu, V. C., Wong, L. Y., Jang, T., Shah, A. H., Park, I., Yang, X., Zhang, Q., Lonning, S., Teicher, B. A., & Lee, C. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.2883 · Cited by 453
Transforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452
Self-citationLaouar, Y., Sutterwala, F. S., Gorelik, L., & Flavell, R. A. (2005) · Nature Immunology · doi:10.1038/ni1197 · Cited by 451
Self-citationBlocking TGF-β–Smad2/3 innate immune signaling mitigates Alzheimer-like pathology
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C. A., Tan, J., Duman, R. S., & Flavell, R. A. (2008) · Nature Medicine · doi:10.1038/nm1781 · Cited by 422
Self-citationInterleukin 2 plays a central role in Th2 differentiation
Cote-Sierra, J., Foucras, G., Guo, L., Chiodetti, L., Young, H. A., Hu-Li, J., Zhu, J., & Paul, W. E. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400339101 · Cited by 420
CD4+CD25+ T Regulatory Cells Suppress NK Cell-Mediated Immunotherapy of Cancer
Smyth, M. J., Teng, M. W. L., Swann, J., Kyparissoudis, K., Godfrey, D. I., & Hayakawa, Y. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.176.3.1582 · Cited by 420
DaCosta Byfield, S., Major, C., Laping, N. J., & Roberts, A. B. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.744 · Cited by 414
Kano, M. R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611660104 · Cited by 410
Chapter 8 The Role of NKT Cells in Tumor Immunity
(2008) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)00408-9 · Cited by 316
Advantages of liposomal delivery systems for anthracyclines
Allen, T. M., & Martin, F. J. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.08.001 · Cited by 248
Létourneau, S., van Leeuwen, E. M. M., Krieg, C., Martin, C., Pantaleo, G., Sprent, J., Surh, C. D., & Boyman, O. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909384107 · Cited by 205
Steric Stabilization of Lipid/Polymer Particle Assemblies by Poly(ethylene glycol)-Lipids
Thevenot, J., Troutier, A.-L., David, L., Delair, T., & Ladavière, C. (2007) · Biomacromolecules · doi:10.1021/bm700753q · Cited by 198
Sanjabi, S., Mosaheb, M. M., & Flavell, R. A. (2009) · Immunity · doi:10.1016/j.immuni.2009.04.020 · Cited by 190
Self-citationAl‐Soufi, W., Reija, B., Novo, M., Felekyan, S., Kühnemuth, R., & Seidel, C. A. M. (2005) · Journal of the American Chemical Society · doi:10.1021/ja0508976 · Cited by 137
Gillies, S. D., Lan, Y., Hettmann, T., Brunkhorst, B. A., Sun, Y., Mueller, S. O., & Lo, K.-M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-2921 · Cited by 95
Management of Metastatic Melanoma
Tawbi, H. A., & Kirkwood, J. M. (2007) · Seminars in Oncology · doi:10.1053/j.seminoncol.2007.09.008 · Cited by 91
Teppler, H., Kaplan, G., Smith, K. A., Montana, A. L., Meyn, P., & Cohn, Z. A. (1993) · The Journal of Experimental Medicine · doi:10.1084/jem.177.2.483 · Cited by 83
Engulfing tumors with synthetic extracellular matrices for cancer immunotherapy
Hori, Y., Stern, P., Hynes, R. O., & Irvine, D. J. (2009) · Biomaterials · doi:10.1016/j.biomaterials.2009.08.037 · Cited by 70
Protein Release from Biodegradable Dextran Nanogels
Thienen, T. G. V., Raemdonck, K., Demeester, J., & Smedt, S. C. D. (2007) · Langmuir · doi:10.1021/la700736v · Cited by 65
Kaufman, H. L., Flanagan, K., Lee, C. S. D., Perretta, D. J., & Hörig, H. (2002) · Vaccine · doi:10.1016/s0264-410x(02)00032-4 · Cited by 55
Liposome-Nanogel Structures for Future Pharmaceutical Applications
Kazakov, S. V., & Levón, K. (2006) · Current Pharmaceutical Design · doi:10.2174/138161206779026281 · Cited by 54
Acquavella, N., Kluger, H. M., Rhee, J., Farber, L. R., Tara, H., Ariyan, S., Narayan, D., Kelly, W. K., & Sznol, M. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318177a4ba · Cited by 51
BIOPHARMACEUTICS OF LIPOSOMAL INTERLEUKIN 2, ONCOLIPIN
Neville, M. E., Boni, L. T., Pflug, L. E., et al. (2000) · Cytokine · doi:10.1006/cyto.2000.0769 · Cited by 21
Kanaoka, E., Takahashi, K., Yoshikawa, T., Jizomoto, H., Nishihara, Y., Uchida, N., Maekawa, R., & Hirano, K. (2002) · Journal of Controlled Release · doi:10.1016/s0168-3659(02)00083-4 · Cited by 18
Enhancing Antitumor Immunity: Combining IL-12 With TGFβ1 Antagonism
Fan, T. M., Kranz, D. M., & Roy, E. J. (2007) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318031a2b2 · Cited by 8
Cited by
Cancer nanomedicine: progress, challenges and opportunities
Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.108 · Cited by 5,873
Overcoming the challenges in administering biopharmaceuticals: Formulation and delivery strategies
Mitragotri, S., Burke, P. A., & Langer, R. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4363 · Cited by 1,702
Functional and Biomimetic Materials for Engineering of the Three-Dimensional Cell Microenvironment
Huang, G., Li, F., Zhao, X., Ma, Y., Li, Y., Lin, M., Jin, G., Lu, T. J., Genin, G. M., & Xu, F. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00094 · Cited by 825
Nanotechnology for protein delivery: Overview and perspectives
Yu, M., Wu, J., Shi, J., & Farokhzad, O. C. (2016) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.10.012 · Cited by 410
Precise nanomedicine for intelligent therapy of cancer
Chen, H., Gu, Z., An, H., Chen, C., Chen, J., Cui, R., Chen, S., Chen, W., Chen, X., Chen, X., et al. (2018) · Science China Chemistry · doi:10.1007/s11426-018-9397-5 · Cited by 409
Metadata
- Authors
- Park, J., Wrzesinski, S. H., Stern, E., Look, M., Criscione, J., Ragheb, R., Jay, S. M., Demento, S. L., Agawu, A., Licona Limon, P., Ferrandino, A. F., Gonzalez, D., Habermann, A., Flavell, R. A., & Fahmy, T. M.
- Venue
- Nature Materials
- Published
- 2012-07-15
- Volume
- 11
- Issue
- 10
- Pages
- 895-905
- ISSN
- 1476-1122 (ISSN-L)
- 1476-4660
- OpenAlex
- W2003690177
- Cited by
- 494
- References
- 46
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.